Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from VTRS

What to Expect From Viatris' Next Quarterly Earnings Report

Viatris is all set to release its fiscal second-quarter earnings next month, and analysts project a double-digit earnings drop.

Barchart

Is Viatris Stock Underperforming the S&P 500?

Viatris has significantly underperformed the S&P 500 over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Viatris' Q1 2025 Earnings Report

Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.

Barchart

How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?

Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.

Barchart

Viatris Stock Outlook: Is Wall Street Bullish or Bearish?

As Viatris has trailed the broader market over the past year, analysts are skeptical about its future outlook.

Barchart

3 Hidden Bargains in the Healthcare Sector

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Viatris Stock: Is VTRS Outperforming the Healthcare Sector?

Despite Viatris’ recent outperformance relative to its broader sector, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?

Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Viatris' Report

Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.

Barchart

Is Viatris Stock Underperforming the Dow?

Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

3 Low P/E Stocks With Strong Growth Prospects

With easing inflation and possibilities of interest rate cuts, investors can rely on stocks like Viatris (VTRS), Open Text (OTEX), and Goodyear Tire & Rubber (GT) with strong growth prospects, trading at affordable prices. Keep reading.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharmaceutical Stocks With Blockbuster Potential

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

StockNews.com

4 Pharma Stocks to Watch for Surprising Gains in June

Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading….

Barchart

Are Wall Street Analysts Bullish on Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain cautious about the stock's prospects.

StockNews.com

3 Top-Rated Pharma Stocks to Diversify Your Portfolio

The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY),…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

StockNews.com

5 Pharma Stocks to Watch With Bullish Momentum

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

StockNews.com

3 Lucrative Pharma Stocks for Portfolio Success

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

Investors Business Daily

These 9 Stocks Are Running To Start 2024

The S&P 500 rebounded last week near record highs, but is up just 0.2% so far in 2024. These are the index's top performers so far.

StockNews.com

Top 4 Pharma Picks for January 2024 Growth

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

StockNews.com

Under $15 Bargains: 3 Pharma Stocks to Watch

The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on….

StockNews.com

3 Stocks to Buy With Less Than $10

The recent collapse of two banks and growing uncertainty about the Fed’s next rate hike amid the strong economic data releases fueled a broad market sell-off lately. However, a volatile market environment offers an attractive opportunity to invest in quality stocks ADT (ADT), Viatris (VTRS), and trivago (TRVG) at reasonable…

1 2

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

722 stories

Neha PanjwaniFrom

97 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.